S'abonner

Challenges in choosing the appropriate guidelines for use in children and adolescents with hypertension - 04/08/21

Doi : 10.1016/j.arcped.2021.05.004 
D.Ö. Hacıhamdioğlu a, , G. Koçak a, B.N. Doğan b, E. Koyuncu b
a Bahçeşehir University Faculty of Medicine, Medical Park Göztepe Hospital, Department of Pediatrics, Division of Pediatric Nephrology, Istanbul, Turkey 
b Bahçeşehir University Faculty of Medicine, Istanbul, Turkey 

Corresponding author. Bahçeşehir University Faculty of Medicine, Medical Park Göztepe Hospital, Department of Pediatrics, Pediatric Nephrology Division, E5 Üzeri 23, Nisan Sk. Merdivenköy No:17, 34732 Kadıköy/İstanbul, Turkey.Bahçeşehir University Faculty of Medicine, Medical Park Göztepe Hospital, Department of Pediatrics, Pediatric Nephrology DivisionE5 Üzeri 23, Nisan Sk. Merdivenköy No:17Kadıköy/İstanbul34732Turkey

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

pages 8
Iconographies 3
Vidéos 0
Autres 0

Abstract

Background

This study was designed to observe the effect of antihypertensive treatment on blood pressure (BP) and target organ damage in patients followed up according to the American Academy of Pediatrics Hypertension Guidelines (AAPG). The results were also assessed in comparison with the definitions and target organ damage according to the European Society of Hypertension Guidelines 2016 (ESHG).

Materials and methods

A total of 44 (34 male) out of 140 patients were enrolled in the study and the mean age was 14±3.19years. The follow-up period was at least 12months. All patients underwent the following assessments: anthropometrical measurements of body mass index (BMI), left ventricular mass index (LVMI), and biochemical parameters according to the relevant guidelines. The pre-treatment and post-treatment datasets collected were compared.

Results

The frequency of symptomatic patients decreased from 88% to 30%. After treatment, 29.4% (n=13) of patients still had elevated and stage 1 hypertension (HT) according to the AAPG. These patients were older and had higher BMI z-scores, LVMI z-scores, mean BP indices, and also had longer symptom duration than normotensive patients (P<0.001). When patients were assessed according to the ESHG, 34.1% (n=15) of patients had high–normal stage 1 and stage 2 HT. While 53.3% (n=8) of the patients aged 13–15years were classified as having high–normal stage 1 and stage 2 HT according to the ESHG, 33.3% (n=5) were classified as having elevated BP and stage 1 HT according to the AAPG. Additionally, 36.4% (n=4) of the patients aged16years were classified as having high–normal and stage 1 HT according to the ESHG, whereas 45.5% (n=5) were classified as having elevated BP and stage 1 HT according to the AAPG.

Conclusion

To control HT in children with higher BMI z-scores, higher LVMI z-scores, and higher BP indices, an earlier and more intensive approach is needed. Considering that the duration of exposure to HT may also affect the LVMI, adjusting age and gender or decreasing the current thresholds for LVMI may lead to an earlier diagnosis for more patients. According to the present classifications, the ESHG covers more children aged between 13 and 15years in contrast to the AAPG, which covers more patients aged16years. However, further studies are needed to confirm these results.

Le texte complet de cet article est disponible en PDF.

Keywords : Hypertension, Children, Obesity, LVMI, LVH


Plan


© 2021  French Society of Pediatrics. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 28 - N° 6

P. 451-458 - août 2021 Retour au numéro
Article précédent Article précédent
  • Impact and projections of the COVID-19 epidemic on attendance and routine vaccinations at a pediatric referral hospital in Cameroon
  • D. Chelo, F. Nguefack, D. Enyama, R. Nansseu, G. Feudjo Tefoueyet, H.D. Mbassi Awa, I. Mekone Nkwelle, G. Nguefack-Tsague, P. Ndenbe, P.O. Koki Ndombo
| Article suivant Article suivant
  • French pediatricians’ views on industry-sponsored clinical trials: Toward stronger research on ethics?
  • S. El Zoghbi, A. Jannot, C. Delacourt, R. Abou Taam, M. Mamzer

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.